Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Keratosis, Actinic 12Warts 11Breast Neoplasms 11Uterine Cervical Dysplasia 7Retinoblastoma 6Prostatic Neoplasms 6Peripheral Nervous System Diseases 6Pain 6Neoplasm Metastasis 6Lung Neoplasms 6Neoplasms 5Stomatitis 4Pancreatic Neoplasms 3Mucositis 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Multiple Myeloma 2Mesothelioma 2Melanoma 2Keratosis 2Condylomata Acuminata 2Carcinoma, Ductal, Breast 2Carcinoma, Basal Cell 2Bone Neoplasms 2Barrett Esophagus 2Adenocarcinoma Of Esophagus 2Wilms Tumor 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Melanoma × Cryotherapy × Clear all
NCT03949153 2025-10-01

CRIRIN

University Hospital, Strasbourg, France

Phase 1/2 Completed
19 enrolled
Dermatologic

Melanoma

NCT05302921 2025-01-01

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Children's National Research Institute

Phase 2 Completed
5 enrolled
CNSDermatologicGastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Melanoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡